Updates

Corporate Office: Registered Office: Star 1, Opp IIM Bangalore, Bilekahalli, Cyber One, Unit No. 902, Sector 30A, Bannergha(cid:425)a Road, Bengaluru – Plot No - 4 & 6, Vashi, 560076, India Navi Mumbai - 400703, India T: +91 80 6784 0738 T: +91 22 2789 2924 Date: July 2, 2026 BSE Limited National Stock Exchange of India Ltd Listing Department- Exchange Plaza, C-1, Block G, Phiroze Jeejeebhoy Towers Bandra Kurla Complex, Dalal Street Bandra (E) Mumbai- 400001 Mumbai – 400 051 Scrip Code: 544292, ISIN: INE013P01021 Symbol: ONESOURCE Dear Sir/ Madam, Subject: Completion of US-FDA Inspection at Sterile Product Division facility at Bengaluru We wish to inform that a routine current Good Manufacturing Practices (cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at the Sterile Product Division facility (SPD) of OneSource Specialty Pharma Limited located at Opp. IIM, Bilekahalli, Bannerghatta Road, Bengaluru, 560076 from June 22, 2026 to June 30, 2026. The inspection has concluded with one observation. The Company will respond to the observation comprehensively to FDA within the stipulated time frame. We will keep the stock exchanges informed of any further developments in this matter. Please take the above information on record. For and on behalf of OneSource Specialty Pharma Limited Trisha A Company Secretary and Compliance Officer Membership Number: A47635 OneSource Specialty Pharma Limited info@onesourcecdmo.com | www.onesourcecdmo.com CIN: L74140MH2007PLC432497